Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice

Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice

Bibliographic Details
Main Authors:	Kasperzyk, J, Hauser, E, D'Azzo, A, Platt, F, Seyfried, T
Format:	Conference item
Published:	2002

Similar Items

Therapeutic assessment of substrate deprivation using NB-DGJ in GM1 storage disease mice
by: Seyfried, T, et al.
Published: (2003)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
by: Kasperzyk, J, et al.
Published: (2004)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
by: Kasperzyk, J, et al.
Published: (2004)

Effects of substrate deprivation therapy on brain lipids in neonatal GML storage disease mice
by: Kasperzyk, J, et al.
Published: (2003)

Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice
by: J.L. Kasperzyk, et al.
Published: (2005-04-01)

"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
by: Kasperzyk, J, et al.
Published: (2005)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005)

Erratum: Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice (Journal of Lipid Research (April 2004) 46 (744-751))
by: Kasperzyk, J, et al.
Published: (2005)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
by: Baek, R, et al.
Published: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
by: Baek, R, et al.
Published: (2008)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
by: Ranes, M, et al.
Published: (2001)

Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review
by: Wenchao Zhang, et al.
Published: (2019-06-01)

GM1 and GM2 gangliosides: recent developments
by: Bisel Blaine, et al.
Published: (2014-03-01)

Influence of ganglioside GM3 and high density lipoprotein on the cohesion of mouse brain tumor cells.
by: H Bai, et al.
Published: (1997-01-01)

AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival.
by: Rena C Baek, et al.
Published: (2010-10-01)

GM1 Gangliosidosis—A Mini-Review
by: Elena-Raluca Nicoli, et al.
Published: (2021-09-01)

Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity
by: Yi-Chen Hsieh, et al.
Published: (2022-09-01)

GM1 ganglioside-independent intoxication by Cholera toxin
by: Cervin, J, et al.
Published: (2018)

GM1 ganglioside-independent intoxication by Cholera toxin.
by: Jakob Cervin, et al.
Published: (2018-02-01)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
by: Elliot-Smith, E, et al.
Published: (2008)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
by: Pshezhetsky, A, et al.
Published: (2017)

Ganglioside GM1 and the Central Nervous System
by: Zhongwu Guo
Published: (2023-05-01)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
by: Pshezhetsky, A, et al.
Published: (2017)

Effect of Golgi membrane phospholipid composition on the molecular species of GM3 gangliosides synthesized by rat liver sialyltransferase.
by: H Kadowaki, et al.
Published: (1994-11-01)

Serum gangliosides in mice with metastatic and non-metastatic brain tumors.
by: M Cotterchio, et al.
Published: (1994-01-01)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
by: Huebecker, M, et al.
Published: (2019)

Characterization of glycan substrates accumulating in GM1 Gangliosidosis
by: Roger Lawrence, et al.
Published: (2019-12-01)

The Key Role of GM1 Ganglioside in Parkinson’s Disease
by: Suman Chowdhury, et al.
Published: (2022-01-01)

Preparation of radiolabeled GM2 and GA2 gangliosides.
by: A Novak, et al.
Published: (1979-07-01)

Ganglioside GM2: a potential biomarker for cholangiocarcinoma
by: Krajang Talabnin, et al.
Published: (2020-07-01)

Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
by: Maria L. Allende, et al.
Published: (2023-12-01)

Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis
by: Natalie M. Deschenes, et al.
Published: (2023-05-01)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
by: Mylene Huebecker, et al.
Published: (2019-11-01)

Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
by: Jay S Schneider, et al.
Published: (2015-01-01)

Disordered testosterone transport in mice lacking the ganglioside GM2/GD2 synthase gene
by: Koichi Furukawa, et al.
Published: (2023-09-01)

Effects of ganglioside GM1 and erythropoietin on spinal cord injury in mice: Functional and immunohistochemical assessments
by: Alessandro Gonzalez Torelli, et al.
Published: (2022-04-01)

Altered expression of ganglioside metabolizing enzymes results in GM3 ganglioside accumulation in cerebellar cells of a mouse model of juvenile neuronal ceroid lipofuscinosis
by: Somogyi, A, et al.
Published: (2018)

Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity[S]
by: Susi Anheuser, et al.
Published: (2015-09-01)

Ganglioside GM3 activates ERKs in human lymphocytic cells
by: Tina Garofalo, et al.
Published: (2002-06-01)

Anti-inflammatory role of GM1 and other gangliosides on microglia
by: Danny Galleguillos, et al.
Published: (2022-01-01)